Focused On-demand Library for Fanconi anemia group B protein

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q8NB91

UPID:
FANCB_HUMAN

ALTERNATIVE NAMES:
Fanconi anemia-associated polypeptide of 95 kDa

ALTERNATIVE UPACC:
Q8NB91; B2RMZ4; Q7Z2U2; Q86XG1

BACKGROUND:
The Fanconi anemia group B protein, with its alternative name Fanconi anemia-associated polypeptide of 95 kDa, is integral to the body's DNA repair machinery. Its primary function involves the necessary ubiquitination of FANCD2, a key step in the DNA damage response pathway.

THERAPEUTIC SIGNIFICANCE:
Linked to the genetic disorder Fanconi anemia complementation group B, this protein's malfunction leads to severe hematological and developmental abnormalities. The exploration of Fanconi anemia group B protein's function offers a promising avenue for developing targeted therapies aimed at correcting the defective DNA repair pathways in affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 21 of 8789